Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Sponsor
Pfizer (Industry)
Overall Status
Available
CT.gov ID
NCT05238311
Collaborator
In Expanded Access, treating physicians are the Sponsors (Other)
Study Details
Study Description
Brief Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
- In Expanded Access, treating physicians are the Sponsors
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer
ClinicalTrials.gov Identifier:
NCT05238311
Other Study ID Numbers:
- C107
First Posted:
Feb 14, 2022
Last Update Posted:
Feb 14, 2022
Last Verified:
Feb 1, 2022